News

This Weight-Loss Stock Sank After Earnings. It’s Still a Risk for Eli Lilly, Novo Nordisk.
Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.
GLP-1 Pill From Eli Lilly Leads to Weight Loss and May Be Available Next Year
In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.
Eli Lilly Has Seized the Lead in Anti-Obesity Drugs. Next Up: a Pill.
The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.
Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might
The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in ...
Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China
More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...
Major insurance changes are coming to GLP-1 drugs for weight loss. Here’s how that could affect patients
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.
NBC Washington1mon
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ...
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.